GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update
by Amy Steele · The Cerbat GemGT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totaling 747,375 shares, a drop of 26.7% from the March 15th total of 1,019,371 shares. Currently, 2.5% of the shares of the stock are sold short. Based on an average daily volume of 654,579 shares, the short-interest ratio is presently 1.1 days.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a report on Friday, April 10th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.
Read Our Latest Stock Report on GT Biopharma
Hedge Funds Weigh In On GT Biopharma
An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC purchased a new stake in GT Biopharma, Inc. (NASDAQ:GTBP – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned 0.47% of GT Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 8.15% of the company’s stock.
GT Biopharma Stock Performance
GTBP traded down $0.00 during trading on Wednesday, reaching $0.39. 304,568 shares of the company’s stock were exchanged, compared to its average volume of 602,376. The company’s fifty day moving average price is $0.45 and its 200-day moving average price is $0.62. GT Biopharma has a fifty-two week low of $0.35 and a fifty-two week high of $3.85. The firm has a market capitalization of $12.24 million, a PE ratio of -0.06 and a beta of 1.19.
GT Biopharma Company Profile
GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.
The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).